Bicycle Therapeutics (BCYC) Q2 2024 earnings summary

Executive summary

• Advanced clinical pipeline focused on oncology, with lead candidate zelenectide pevedotin in Phase II/III trials and multiple ongoing collaborations with major pharmaceutical partners.

• Four clinical pipeline abstracts accepted for ESMO Congress 2024, highlighting progress in oncology programs.

• R&D pipeline prioritized on zelenectide pevedotin and BT5528, with focus on high-value clinical programs.

• Leadership team streamlined and Clinical Advisory Board formed to enhance oncology expertise.

• FDA granted Fast Track Designation to zelenectide pevedotin and BT5528 for urothelial cancer; pipeline prioritization announced in August 2024 to focus on BTC molecules and BRC pipeline.

Financial highlights

• Cash and cash equivalents of $961.4 million as of June 30, 2024, up from $526.4 million at year-end 2023, primarily due to a $555.5 million private placement.

• Net loss for Q2 2024 was $39.8 million, or $(0.77) per share, compared to $42.6 million, or $(1.41) per share, in Q2 2023.

• R&D expenses were $40.1 million for Q2 2024, up slightly from $39.7 million in Q2 2023.

• General and administrative expenses rose to $15.9 million from $14.8 million year-over-year.

• Gross proceeds of $555.5 million raised in May 2024 PIPE financing, extending financial runway into 2H 2027.

Outlook and guidance

• Cash runway expected to fund operations and capital expenditures into the second half of 2027.

• Near-term research to focus on advancing the Bicycle Radionuclide Conjugate pipeline and next-generation BTC molecules.

• Anticipates increased expenses as clinical and preclinical programs advance, with continued operating losses expected in the foreseeable future.

• Additional funding may be required for long-term growth and commercialization efforts.

• Continued prioritization of clinical programs with highest value creation potential.